Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2020 Jan 3;6(1):e46-e49.
doi: 10.4158/ACCR-2019-0211. eCollection 2020 Jan-Feb.

MANIFESTATIONS OF GLUCAGONOMA SYNDROME

Case Reports

MANIFESTATIONS OF GLUCAGONOMA SYNDROME

Mauricio Alvarez et al. AACE Clin Case Rep. .

Abstract

Objective: Glucagonoma is a rare neuroendocrine tumor of the pancreas. We present the case of a young female patient who presented with the major clinical manifestations of glucagonoma syndrome.

Methods: The major clinical manifestations of glucagonoma syndrome are described in a 44-year-old, female patient. Beyond glucagonoma, the patient also displayed deep venous thrombosis, depression, diabetes, and necrolytic migratory erythema. We discuss the difficulty of treatment of patients with glucagonoma due to the low prevalence of the disorder, scarcity of medical evidence, lateness of diagnosis with liver metastases in most cases, and poor response to chemotherapy with high rates of relapse after surgery. In this case, pancreatectomy and hepatic lobectomy followed by somatostatin analogue therapy was the chosen treatment strategy.

Results: The clinical findings were pancreatic and hepatic masses, proximal deep venous thrombosis, depression, diabetes, and necrolytic migratory erythema. The patient also had elevated levels of glucagon. Pancreatectomy and right hepatic lobectomy were performed and confirmed the glucagonoma.

Conclusion: Our case adds new knowledge about glucagonoma which is important due to the low incidence of the disease and the particular characteristics of the syndrome.

PubMed Disclaimer

Conflict of interest statement

DISCLOSURE The authors have no multiplicity of interest to disclose.

Figures

Fig. 1.
Fig. 1.
Migratory necrolytic erythema on the face showing hyperpigmented and erythematous lesions.
Fig. 2.
Fig. 2.
Cheilitis and glossitis.
Fig. 3.
Fig. 3.
Axial computed tomography of the abdomen showing masses in the pancreatic tail and right hepatic lobe.
Fig. 4.
Fig. 4.
Histology (×40) showing nodular and trabecular structures formed by cells with broad, granular eosinophilic cytoplasm and homogeneous nuclei. Slight pleomorphism and some visible nucleoli are also observed, but no important mitotic activity is observed.

References

    1. Wei J, Lin S, Wang C et al. Glucagonoma syndrome: a case report. Oncol Lett. 2015;10:1113–1116. - PMC - PubMed
    1. John AM, Schwartz RA. Glucagonoma syndrome: a review and update on treatment. J Eur Acad Dermatol Venereol. 2016;30:2016–2022. - PubMed
    1. Rodríguez G, Vargas E, Abaúnza C, Cáceres S. Necrolytic migratory erythema and pancreatic glucagonoma. Biomedica. 2016;36:176–181. - PubMed
    1. Fang S, Li S, Cai T. Glucagonoma syndrome: a case report with focus on skin disorders. Onco Targets Ther. 2014;7:1449–1453. - PMC - PubMed
    1. Al-Faouri A, Ajarma K, Alghazawi S, Al-Rawabdeh S, Zayadeen A. Glucagonoma and glucagonoma syndrome: a case report with review of recent advances in management. Case Rep Surg. 2016;2016 1484089. - PMC - PubMed

Publication types

LinkOut - more resources